On the other hand 44% of patients received “off-label” drugs (22% rituximab, 11% anti-D, 7% ciclosporin, 4% danazol), when only the following drugs were approved in Germany for the treatment of immune thrombocytopenia: steroids, immunoglobulins, azathioprine, thrombopoietin receptor agonists and vinca alkaloids. This evidence concerns the gene MPL and autoimmune thrombocytopenic purpura.